Melio Bio leverages human genetics to improve cardiometabolic health.

Melio Bio

Planetary Group builds, owns, and operates a global network of fermentation facilities to produce bio-based products at scale. It uses a proprietary BioBlocksTM fermentation and AI platform for optimal production.

Planetary Group

Melio Bio | 368 followers on LinkedIn. Leveraging human genetics for better cardiometabolic health | Melio Bio is co-created with M:M Bio. A biotechnology company focussed on discovering and developing novel inhibitors of GPCRs critically implicated in cardiometabolic disease.

I will be at #BIOEurope to talk about seed stage companies in Molecule to Medicine 's London pod. This pod is focused on building therapeutic biotech companies in the #metabolic disease space. Melio Bio is building on our collective intelligence of difficult to target GPCRs, and is focused on the discovery and development of small molecule modulators of GPR75, a genetically validated target in metabolic disease. The second company in the London pod is in stealth mode, developing novel biologics to inhibit a pathway with strong genetic associations with cardiometabolic disease. Both companies are supported by MTM's #bioinformatics platform. Send me a message if you would like to meet me to learn more in Stockholm or use the partnering platform Informa Connect

Zoë Johnson

🌍 Meet the MTM ecosystem at BIO Europe! 🌱 Representatives from across the Molecule to Medicine ecosystem will be in Stockholm from November 4th-6th for the #BIOEurope conference! Our CSO/CDO Zoë Johnson will be there to talk about seed-stage companies in MTM's metabolic disease-focused London pod, including Melio Bio Pathios Therapeutics ’ CEO Paul G Higham and CSO Stuart Hughes will be talking to potential partners about the company’s pioneering use of GPR65 antagonists for the potential treatment of certain solid tumours Grey Wolf Therapeutics ’ COO/CBO Andy Page and Senior Business Development Manager Alexander Spicer will be talking about the company’s novel antigen modulation technology which controls T cell responses and has potential applications in autoimmune disease and cancer. Our team is eager to engage with investors and potential partners who share our passion for driving advancements in life sciences. Together, we are transforming the future of healthcare. Learn more at www.moleculetomedicine.com Let’s shape the future together! 🤝✨ #BioEurope2024 #Networking #Innovation #Biotech #MTMEcosystem #BioEurope #CollectiveIntelligence #ImmunoOncology #BioEuro #Biology #Oncology

Molecule to Medicine

Melio Bio is proud to be part of the dynamic and pioneering ecosystem created by Molecule to Medicine (MTM). We benefit from shared learnings from our sister companies, all of which are driving innovative science into the clinic at industry beating speed, whilst maintaining our commitment to excellence. 👀 Take a peek at the fresh, new-look MTM website and see what you think! www.moleculetomedicine.com

David Miller represented Melio Bio at the 60th annual European Association for the Study of Diabetes e.V. (EASD) conference in Madrid this week and we can't wait to hear what he has learned. It is an exciting time to be working in the #metabolicdisease space. Stay tuned as we work towards bringing innovative molecules to improve the lives of patients burdened by #diabetes #obesity #MASLD #PAH

📢 Join our co-founder David Miller this morning at #BioSeed summer and hear about our plans for Melio Bio ! David will be joined by Zoë Johnson - come and find us in the breakout sessions, we will be happy to tell you more. BioSeed, organised by OBN (UK) Ltd , is a fast-paced, one-day pitching event where #innovative early-stage life sciences companies seeking #Seedfunding , showcase to and meet with an extensive audience of active life sciences #investors . https://lnkd.in/gaPY85am

M:M Bio and its drug discovery partner, Sygnature Discovery are proud to announce the launch of the fourth company in the M:M Bio ecosystem, and the first in our London pod. Melio Bio is focused on the discovery and development of inhibitors of #GPCRs implicated in #cardiometabolic disease including Type 2 diabetes, pulmonary hypertension, #obesity and stroke. M:M Bio co-creates, builds, and scales #biotech companies. Run by entrepreneurs for entrepreneurs, the M:M ecosystem integrates experienced drug discovery expertise with stage appropriate, agile, operational infrastructure that results in companies that are efficient, cost effective, focused and great places to work. By partnering with Sygnature Discovery, a world-leading integrated drug discovery partner with broad expertise and track record in GPCRs, and metabolic disease, Melio Bio will deliver best-in-class inhibitors to potentially treat patients suffering with metabolic diseases that are poorly treated by existing therapeutic options.

Metric
Company Name	Melio Bio	Planetary Group
Symbol
MSH ID	BIO:MELIO	CH:PLANETARYGROUP
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Consumer Goods
Industry	Biotechnology	Food & Beverage
Country	US	CH
Stage
Employee Count		11
Website	melio.bio	planetarygroup.ch
LinkedIn	melio-bio	planetarygroup
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		5.65K
Web Traffic Growth		-0.83
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

MELI

BIO:MELIO

Melio Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue